OSMITROL Injection (Mannitol Injection, USP)
in VIAFLEX Plastic Container
For Therapeutic Use Only
OSMITROL Injection (Mannitol Injection, USP) is a sterile, nonpyrogenic solution of Mannitol, USP in a single dose container for intravenous administration. It contains no antimicrobial agents. Mannitol** is a six carbon sugar alcohol prepared commercially by the reduction of dextrose. Although virtually inert metabolically in humans, it occurs naturally in fruits and vegetables. Mannitol is an obligatory osmotic diuretic. The pH is adjusted with sodium hydroxide or hydrochloric acid.
OSMITROL Injection (Mannitol Injection, USP) is indicated for:
The promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established;
The reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass;
The reduction of elevated intraocular pressure when the pressure cannot be lowered by other means, and
Promoting the urinary excretion of toxic substances.
Published Studies Related to Osmitrol (Mannitol)
Effect of mannitol on postreperfusion cardiac output and central venous oxygen
saturation during orthotopic liver transplant: a double-blind randomized clinical
central venous oxygen saturation... CONCLUSION: Infusion of mannitol 1 g/kg during the anhepatic phase was effective
Pooled analysis of two large randomised phase III inhaled mannitol studies in
cystic fibrosis. 
subgroups of a large global CF population... CONCLUSIONS: Sustained six-month improvements in lung function and decreased
Long-term inhaled dry powder mannitol in cystic fibrosis: an international
randomized study. 
osmotic agent, improves lung function and morbidity... CONCLUSIONS: Inhaled mannitol, 400 mg twice a day, resulted in improved lung
Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria. [2011.04.13]
CONCLUSIONS: There are insufficient data to know what the effects of osmotic diuretics are in children with cerebral malaria. Larger, multicentre trials are needed.
Small bowel preparations for capsule endoscopy with mannitol and simethicone: a prospective, randomized, clinical trial. [2011.04]
BACKGROUND AND OBJECTIVE: There is no consensus concerning small bowel preparation before capsule endoscopy (CE). This study evaluated the effects of 4 regimens on small bowel cleansing and diagnostic yield... CONCLUSIONS: Small bowel preparation that involves split-dose oral mannitol plus single-dose simethicone for CE can improve mucosal visualization and subsequent diagnostic yield when compared with 10-hours overnight fasting.
Clinical Trials Related to Osmitrol (Mannitol)
Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis [Completed]
The purpose of this study is to determine the medium term efficacy and safety profile of
inhaled mannitol, on its own and also as an additional therapy to rhDNase (pulmozyme). In
particular, we will assess the impact on: lung function; airway inflammation; sputum
microbiology; exacerbations; quality of life; adverse events; exercise tolerance; total costs
of hospital and community care; and cost-effectiveness.
Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis [Recruiting]
No gold standard therapy exists for clearing mucus from the airways of patients with
bronchiectasis. While rhDNase has a proven place in the treatment of CF, it failed to
improve FEV1 in a short-term non-CF bronchiectasis study and has been shown to be
detrimental after 6 months therapy in non CF bronchiectasis, moreover it has no proven
effect on mucociliary clearance. Hypertonic saline has been shown to have a comparable mode
of action to inhaled mannitol, but has yet to be examined as a long term treatment option in
The purpose of this study is to examine the efficacy and safety of 52 weeks treatment with
inhaled mannitol in subjects with non-cystic fibrosis bronchiectasis. Previous studies with
inhaled mannitol have demonstrated improvement in mucociliary clearance; mucus rehydration;
improvement in quality of life and respiratory symptoms in patients with bronchiectasis and
pulmonary function in cystic fibrosis. The results of this current study in combination
with a recently completed 3 month study seek to confirm these early findings and to extend
the evidence to support its use as a mucoactive therapy in subjects with bronchiectasis.
We hypothesize that mannitol will improve the overall health and hygiene of the lung through
regular and effective clearing of the mucus load. As a consequence of the reduction in mucus
load and inflammatory process, the frequency of bronchiectasis related pulmonary
exacerbations and the need for exacerbation related antibiotic treatment should fall. Days
in hospital and community health care costs are expected to change in line with improvements
in respiratory health.
Finally, we plan to demonstrate that inhaled mannitol is safe and well tolerated over a 52
week period. We will test these hypotheses using 400 mg mannitol twice daily against
Measurement of Exhaled Nitric Oxide (NO) and Bronchial Provocation Test With Mannitol as a Predictor of Response to Inhaled Corticosteroids in Chronic Cough [Recruiting]
Chronic cough is defined by its persistence beyond 8 weeks. Many conditions can explain the
existence of a bronchial inflammation. In the management of chronic cough, the search for
bronchial hyperreactivity (HRB) is recommended. The treatment relies primarily on the
prescription of inhaled corticosteroids. It has been shown recently that the existence of an
HRB with Methacholine (bronchial provocation test used in routine) does predict the
effectiveness of inhaled corticosteroid treatment in no more than 50% of cases.
It is now possible to assess the bronchial inflammation by rapid, non-invasive and
reproducible tests such that the fraction of exhaled nitric oxide (FeNO) and bronchial
provocation test with mannitol. In a retrospective study, it was shown that an increased
value of FeNO (cut-off > 35 ppb) predicts a positive response to treatment with a
sensitivity of 90% and a specificity of 80%.
Mannitol Challenge Test in Adult Asthma Patients With Fixed Dose Combinations [Recruiting]
The primary objective in this pilot study is to explore if asthma patients prescribed fixed
dose combinations (budenosid/formoterol (Symbicort®), salmeterol/fluticasone (Seretide®),
beclometasone/formoterol (Innovair®) are optimal treated regarding the mannitol challenge
test and the following reversibility test.
The primary endpoint is to identify asthma patients responding positive or negative to the
mannitol challenge test and/or the reversibility test.
The hypothesis is that not all patients are well treated.
Mannitol Versus Hypertonic Saline to Treat Intracranial Hypertension (ICHT) After Severe Traumatic Brain Injury (TBI) : Comparative Effects on PtiO2 and Microdialysis Values [Recruiting]
The purpose of this study is to determine whether hypertonic saline is as much effective as
mannitol to treat intracranial hypertension after traumatic brain injury and has at least
the same effects on PtiO2 and cerebral metabolism studied through microdialysis.